TWI767119B

Glufosfamide or its analogues have specific inhibitory effects on cells with specific genetic variations, more specifically, on cells with damaged DNA repair. The cell or tissue has at least one or more gene mutations of BRCA1, BRCA2, FANCD1, FANCD2, ATM, ATR, CHEK1, CHEK2, CTP, BARD1, BRIP1, PALB2, RAD51D, RAD51C, RAD52, RAD54, RAD55, RAD57, FAM175, NBN, Rad50, MER11, p53, NBS1, XRS2, XRCC2, XRCC3, ERCC1, ERCC2, ERCC3, ERCC4, XRCC1, Ku80, MHS6, MGMT, PARP or ERCC5. The analogues refer to an ester obtained by esterification of one or more hydroxyl groups in the glufosfamide molecule with organic acids and inorganic oxyacids; an ester obtained by esterification of one or more hydroxyl groups in the glufosfamide molecule with an amino acid; the salt obtained by the reaction of a glufosfamide molecule with an acid. As such, the medical use of glufosfamide or its analogues in the treatment of tumors and cancer diseases in cancer patients with specific genetic variations is provided.